ImmunityBio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IBRX Nasdaq 2836 immunitybio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for ImmunityBio, Inc.

ImmunityBio, Inc. (IBRX) Posts Strong Preliminary Q1 Sales on ANKTIVA Momentum - Apr 13th, 2026 3:29 am
IBRX Stock Rises 7% on Strong Q1 2026 Preliminary Results - Apr 10th, 2026 12:54 pm
ImmunityBio Reports Net Product Revenue Increased Nearly 2.7 Times Year-Over-Year to Record $44 Million in Q1 2026 and $381 Million in Cash and Marketable Securities - Apr 9th, 2026 5:30 am
IBRX Responds to FDA Warning Over Misleading Cancer Drug Claims - Apr 7th, 2026 6:58 am
Is ImmunityBio’s (IBRX) FDA Promotion Setback Reframing the Stock’s Risk and Credibility Narrative? - Apr 7th, 2026 2:12 am
Why ImmunityBio Stock Slumped on Monday - Apr 6th, 2026 6:01 pm
ImmunityBio (IBRX) Faces FDA Warning, BTIG Stays Positive - Apr 6th, 2026 3:08 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Apr 6th, 2026 1:50 pm
Sector Update: Health Care Stocks Softer Monday Afternoon - Apr 6th, 2026 11:46 am
ImmunityBio And 2 Insider Picks For Promising Growth - Apr 6th, 2026 11:35 am
ImmunityBio Addresses FDA Correspondence and Reaffirms Commitment to Advertising Compliance - Apr 6th, 2026 5:30 am
ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion - Apr 1st, 2026 12:48 am
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Volatile Share Price Swings - Mar 31st, 2026 6:18 pm
Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec” - Mar 31st, 2026 10:36 am
ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement - Mar 31st, 2026 9:06 am
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline - Mar 31st, 2026 5:30 am
ImmunityBio Lead Bladder Cancer Drug Trial Clears Power Check - Mar 28th, 2026 6:31 pm
ImmunityBio vs. Moderna: Which Biotech Has More Upside Potential? - Mar 27th, 2026 7:11 am
ImmunityBio Confirms Statistical Power in Pivotal Randomized BCG-Naïve NMIBC Trial to Detect Clinically Meaningful Differences Between ANKTIVA® Plus BCG Versus BCG Alone; Supplemental BLA Submission on Track for 2026 - Mar 26th, 2026 5:30 am
FDA Warning Puts ImmunityBio Anktiva Hopes And Valuation In Focus - Mar 26th, 2026 5:08 am